Letters to the EditorRituximab-Induced Acute Pulmonary Fibrosis
REFERENCES (2)
- et al.
Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance
J Clin Oncol
(1999) - et al.
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapse indolent lymphoma: half of patients respond to a four-dose treatment program
J Clin Oncol
(1998)
Cited by (47)
Effect of rituximab on pulmonary function in patients with rheumatoid arthritis
2016, Pulmonary Pharmacology and TherapeuticsRenal and pulmonary late effects of cancer therapy
2013, Seminars in OncologyPulmonary Complications of Anticancer Treatment
2013, Abeloff's Clinical Oncology: Fifth EditionRituximab-induced acute eosinophilic pneumonia with diffuse alveolar damage: A case report
2011, Journal of Experimental and Clinical MedicineCitation Excerpt :Rituximab, a chimeric monoclonal antibody targeting CD20, is widely used in the treatment of B-cell neoplasms.1–5 But some unexpected adverse effects with lethal potential may occur in patients treated with rituximab,6–9 which probably impede its further use. Recently, much attention has been paid to acute respiratory reactions, including interstitial pneumonitis,9–14 bronchiolitis obliterans with organizing pneumonia (BOOP),15,16 diffuse alveolar hemorrhage8–10 and pulmonary fibrosis.7
Interstitial Lung Disease Induced or Exacerbated by TNF-Targeted Therapies: Analysis of 122 Cases
2011, Seminars in Arthritis and RheumatismPulmonary complications of cancer therapy and central airway obstruction
2011, Supportive Oncology: (Expert Consult - Online and Print)
Copyright © 2004 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.